Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24568584 | 0.76 | DPP4 (0.30) | — | |
| SCHEMBL25134488 | 0.73 | TAS1R3 (0.46) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL22298130 | 0.73 | CA2 (0.42) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL16847599 | 0.73 | ALDH1A1 (0.35) | CA2ALDH1A1SMN1; SMN2 | |
| SCHEMBL25135055 | 0.73 | TAS1R3 (0.46) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL25372952 | 0.73 | CYP2D6 (0.32) | — | |
| SCHEMBL24709755 | 0.73 | CA2 (0.42) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL25135063 | 0.73 | TAS1R3 (0.46) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL24785343 | 0.73 | CA2 (0.42) | CA2ESR1KCNH2ALDH1A1POLB | |
| SCHEMBL1120103 | 0.73 | CYP2D6 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080570-B2 | α2B and α2C agonists | ALLERGAN, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090275627-A1 | ALPHA2B AND ALPHA2C AGONISTS | ALLERGAN, INC. (US) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275627-A1 | ALPHA2B AND ALPHA2C AGONISTS | ADRA2B, ADRA2C, ADRB2 | CA2 1143/4885ESR1 1456/4885KCNH2 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.